retatrutide triple agonist gip glp-1 glucagon phase 3 2025 is a triple-agonist drug targeting GLP-1, GIP, and receptors to suppress appetite and boost thermogenesis. 2 trials reported 24.2% average weight loss and over 80% liver fat reduction, reversing Retatrutide TRIUMPH-4 Results: Are We
Pay in 4 interest-free payments of $7.20 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
























